Sign In
Buy ABUS
$4.35
+0.0900 (+2.11%)
At Close: Jun 03, 2026
Arbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive Investment
07:29pm, Friday, 19'th Nov 2021
Recent Acquisition of RNAi drug maker Dicerna by Novo Nordisk makes a case for eventual partnership/buyout of Arbutus Biopharma. AB-729 has proven to work in treating patients with Hepatitis B with si
Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q3 2021 Results - Earnings Call Transcript
02:15pm, Thursday, 04'th Nov 2021
Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q3 2021 Results - Earnings Call Transcript
5 Short Squeeze Penny Stocks To Watch For November 2021
11:16am, Tuesday, 26'th Oct 2021
Are these penny stocks ready to short squeeze? The post 5 Short Squeeze Penny Stocks To Watch For November 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Arbutus to Report Third Quarter 2021 Financial Results and Provide Corporate Update
07:30am, Thursday, 21'st Oct 2021
WARMINSTER, Pa., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commerciali
Best Penny Stocks To Buy This Week? 10 With Potential Biotech Catalysts
10:45am, Sunday, 10'th Oct 2021
Are these 10 penny stocks on your watch list this week? The post Best Penny Stocks To Buy This Week?
5 Penny Stocks To Watch This Week With Potential Biotech Catalysts
10:45am, Sunday, 03'rd Oct 2021
Will upcoming events mean big things for these penny stocks? The post 5 Penny Stocks To Watch This Week With Potential Biotech Catalysts appeared first on Penny Stocks to Buy, Picks, News and Informat
Arbutus to Participate in October Investor Conferences
07:30am, Tuesday, 28'th Sep 2021
WARMINSTER, Penn., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commerci
Do Options Traders Know Something About Arbutus Biopharma (ABUS) Stock We Don't?
10:03am, Monday, 27'th Sep 2021
Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.
Arbutus Appoints Lisa M. Caperelli as Vice President, Investor Relations
07:30am, Tuesday, 21'st Sep 2021
WARMINSTER, Pa., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercial
ABUS Stock: Why It Increased This Week
08:10am, Friday, 10'th Sep 2021
The stock price of Arbutus Biopharma Corp (NASDAQ: ABUS) increased more than 12.5% over the past few trading days. This is why it happened.
Is the Options Market Predicting a Spike in Arbutus Biopharma (ABUS) Stock?
09:56am, Monday, 23'rd Aug 2021
Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.
Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q2 2021 Results - Earnings Call Transcript
03:06pm, Thursday, 05'th Aug 2021
Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q2 2021 Results - Earnings Call Transcript
Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates
10:39am, Thursday, 05'th Aug 2021
Arbutus (ABUS) delivered earnings and revenue surprises of -9.52% and 12.35%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Arbutus Reports Second Quarter 2021 Financial Results and Provides Corporate Update
07:30am, Thursday, 05'th Aug 2021
New data on AB-729, Arbutus' proprietary subcutaneously delivered RNAi agent, highlighted in four abstracts at the EASL International Liver Congress™ ; all AB-729 abstracts selected for best of ILC�
Arbutus to Present at Wedbush PacGrow Healthcare Virtual Conference
08:00am, Tuesday, 03'rd Aug 2021
WARMINSTER, Pa., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commerciali
